Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

生存素基因多态性与由丙型肝炎病毒引起肝癌风险的埃及患者的关系

卷 21, 期 6, 2021

发表于: 02 March, 2021

页: [536 - 543] 页: 8

弟呕挨: 10.2174/1568009621666210302090917

价格: $65

conference banner
摘要

背景：本研究旨在探讨生存素基因多态性与因丙肝感染而发生肝癌(HCC)风险的埃及患者之间的关系。 方法：这项前瞻性研究对164例患者进行了研究，其中57例诊断为丙肝，57例诊断为HCC，另外还有50名健康志愿者作为对照。采用RT-PCR技术对生存素 rs1042489和rs8073069单核苷酸多态性进行基因分型。 结果：生存素 rs1042489多态性结果显示，肝癌患者TC和CC基因型与对照组相比差异显著(OR=15.5, 95%CI: 3.299 ~ 72.825,P<0.001)，与对照组相比差异显著(OR=44, 95%CI: 8.025 ~ 241.254, P<0.001)。CC基因型在肝硬化和肝癌患者中差异有统计学意义(OR=19.2, 95%CI: 3.097-119.049, P=0.002)。TC基因型在对照组和肝硬化患者之间差异有统计学意义(OR=5.5, 95%CI: 2.111 ~ 14.328, P<0.001)。然而，在比较TT基因型时，CC+TC基因型结果显示与肝硬化和肝癌风险增加显著相关(OR=4.812, 95%CI: 1.893-12.233, P=0.001)， (OR=21.607, 95%CI: 4.738-98.532, P<0.01)。另一方面，生存素rs8073069基因型在所有研究组间无显著差异。此外，与GG基因型相比，CC+GC基因型与肝癌风险增加无显著相关性(P=0.999)。 结论：研究表明，功能性生存素 rs1042489多态性可能与肝癌发生风险有关，而生存素 rs8073069多态性与肝癌发生风险的增加无显著相关性。

关键词: HCC

« Previous
[1]
Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin., 2005, 55(2), 74-108.
[http://dx.doi.org/10.3322/canjclin.55.2.74] [PMID: 15761078]
[2]
El-Serag, H.B.; Rudolph, K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007, 132(7), 2557-2576.
[http://dx.doi.org/10.1053/j.gastro.2007.04.061] [PMID: 17570226]
[3]
Dragani, T.A. Risk of HCC: genetic heterogeneity and complex genetics. J. Hepatol., 2010, 52(2), 252-257.
[http://dx.doi.org/10.1016/j.jhep.2009.11.015] [PMID: 20022654]
[4]
Farazi, P.A.; DePinho, R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer, 2006, 6(9), 674-687.
[http://dx.doi.org/10.1038/nrc1934] [PMID: 16929323]
[5]
Ludwig, J.A.; Weinstein, J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer, 2005, 5(11), 845-856.
[http://dx.doi.org/10.1038/nrc1739] [PMID: 16239904]
[6]
Shepelev, M.V.; Kopantzev, E.P.; Vinogradova, T.V.; Sverdlov, E.D.; Korobko, I.V. hTERT and BIRC5 gene promoters for cancer gene therapy: A comparative study. Oncol. Lett., 2016, 12(2), 1204-1210.
[http://dx.doi.org/10.3892/ol.2016.4718] [PMID: 27446419]
[7]
Yamamoto, T.; Tanigawa, N. The role of survivin as a new target of diagnosis and treatment in human cancer. Med. Electron Microsc., 2001, 34(4), 207-212.
[http://dx.doi.org/10.1007/s007950100017] [PMID: 11956993]
[8]
Tamm, I.; Wang, Y.; Sausville, E.; Scudiero, D.A.; Vigna, N.; Oltersdorf, T.; Reed, J.C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res., 1998, 58(23), 5315-5320.
[PMID: 9850056]
[9]
Asanuma, K.; Moriai, R.; Yajima, T.; Yagihashi, A.; Yamada, M.; Kobayashi, D.; Watanabe, N. Survivin as a radioresistance factor in pancreatic cancer. Jpn. J. Cancer Res., 2000, 91(11), 1204-1209.
[http://dx.doi.org/10.1111/j.1349-7006.2000.tb00906.x] [PMID: 11092988]
[10]
Yazdani, N.; Sayahpour, F.A.; Haghpanah, V.; Amiri, P.; Shahrabi-Farahani, M.; Moradi, M.; Mirmiran, A.; Khorsandi, M.T.; Larijani, B.; Mostaan, L.V.; Amoli, M.M. Survivin gene polymorphism association with papillary thyroid carcinoma. Pathol. Res. Pract., 2012, 208(2), 100-103.
[http://dx.doi.org/10.1016/j.prp.2011.12.009] [PMID: 22293278]
[11]
Borbély, A.A.; Murvai, M.; Szarka, K.; Kónya, J.; Gergely, L.; Hernádi, Z.; Veress, G. Survivin promoter polymorphism and cervical carcinogenesis. J. Clin. Pathol., 2007, 60(3), 303-306.
[http://dx.doi.org/10.1136/jcp.2006.037804] [PMID: 16714396]
[12]
Watany, M.; Badawi, R.; Elkhalawany, W.; Abd-Elsalam, S. Study of dickkopf-1 (DKK-1) gene expression in hepatocellular carcinoma patients. J. Clin. Diagn. Res., 2017, 11(2), OC32-OC34.
[http://dx.doi.org/10.7860/JCDR/2017/23095.9450] [PMID: 28384913]
[13]
El-Gebaly, F.; Abou-Saif, S.; Elkadeem, M.; Helmy, A.; Abd-Elsalam, S.; Yousef, M.; Elkhouly, R.A.; Amer, I.F.; El-Demerdash, T. Study of serum soluble programmed death ligand 1 as a prognostic factor in hepatocellular carcinoma in egyptian patients. Curr. Cancer Drug Targets, 2019, 19(11), 896-905.
[http://dx.doi.org/10.2174/1568009619666190718141647] [PMID: 31538897]
[14]
Kawata, N.; Tsuchiya, N.; Horikawa, Y.; Inoue, T.; Tsuruta, H.; Maita, S.; Satoh, S.; Mitobe, Y.; Narita, S.; Habuchi, T. Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility. Int. J. Cancer, 2011, 129(8), 1872-1880.
[http://dx.doi.org/10.1002/ijc.25850] [PMID: 21154810]
[15]
Hsieh, Y.S.; Tsai, C.M.; Yeh, C.B.; Yang, S.F.; Hsieh, Y.H.; Weng, C.J. Survivin T9809C, an SNP located in 3′-UTR, displays a correlation with the risk and clinicopathological development of hepatocellular carcinoma. Ann. Surg. Oncol., 2012, 19(3)(Suppl. 3), S625-S633.
[http://dx.doi.org/10.1245/s10434-011-2123-3] [PMID: 22052111]
[16]
Jaiswal, P.K.; Goel, A.; Mandhani, A.; Mittal, R.D. Functional polymorphisms in promoter survivin gene and its association with susceptibility to bladder cancer in North Indian cohort. Mol. Biol. Rep., 2012, 39(5), 5615-5621.
[http://dx.doi.org/10.1007/s11033-011-1366-1] [PMID: 22193624]
[17]
Schur, B.C.; Bjerke, J.; Nuwayhid, N.; Wong, S.H. Genotyping of cytochrome P450 2D6*3 and *4 mutations using conventional PCR. Clin. Chim. Acta, 2001, 308(1-2), 25-31.
[http://dx.doi.org/10.1016/S0009-8981(01)00422-3] [PMID: 11412814]
[18]
Weng, C.J.; Hsieh, Y.H.; Chen, M.K.; Tsai, C.M.; Lin, C.W.; Yang, S.F. Survivin SNP-carcinogen interactions in oral cancer. J. Dent. Res., 2012, 91(4), 358-363.
[http://dx.doi.org/10.1177/0022034512438402] [PMID: 22318371]
[19]
Chan, Y. Biostatistics 102: quantitative data–parametric & non-parametric tests. blood pressure., 2003.
[20]
Chan, Y.H. Biostatistics 103: qualitative data - tests of independence. Singapore Med. J., 2003, 44(10), 498-503.
[PMID: 15024452]
[21]
Chan, Y.H. Biostatistics 104: correlational analysis. Singapore Med. J., 2003, 44(12), 614-619.
[PMID: 14770254]
[22]
Cohen, C.; Lohmann, C.M.; Cotsonis, G.; Lawson, D.; Santoianni, R. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod. Pathol., 2003, 16(6), 574-583.
[http://dx.doi.org/10.1097/01.MP.0000073868.31297.B0] [PMID: 12808063]
[23]
Gazouli, M.; Tzanakis, N.; Rallis, G.; Theodoropoulos, G.; Papaconstantinou, I.; Kostakis, A.; Anagnou, N.P.; Nikiteas, N. Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int. J. Colorectal Dis., 2009, 24(2), 145-150.
[http://dx.doi.org/10.1007/s00384-008-0601-2] [PMID: 18946675]
[24]
Chen, J.; Cui, X.; Zhou, H.; Qin, C.; Cao, Q.; Ju, X.; Li, P.; Cai, H.; Zhu, J.; Meng, X.; Wang, M.; Zhang, Z.; Shao, P.; Li, J.; Yin, C. Functional promoter -31G/C variant of Survivin gene predict prostate cancer susceptibility among Chinese: a case control study. BMC Cancer, 2013, 13(1), 356.
[http://dx.doi.org/10.1186/1471-2407-13-356] [PMID: 23883402]
[25]
Javid, J.; Mir, R.; Julka, P.K.; Ray, P.C.; Saxena, A. Role of survivin re-expression in the development and progression of non-small cell lung cancer. Tumour Biol., 2015, 36(7), 5543-5550.
[http://dx.doi.org/10.1007/s13277-015-3224-6] [PMID: 25677909]
[26]
Xu, Y.; Fang, F.; Ludewig, G.; Jones, G.; Jones, D. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol., 2004, 23(9), 527-537.
[http://dx.doi.org/10.1089/dna.2004.23.527] [PMID: 15383173]
[27]
Ambrosini, G.; Adida, C.; Altieri, D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med., 1997, 3(8), 917-921.
[http://dx.doi.org/10.1038/nm0897-917] [PMID: 9256286]
[28]
Knizhnik, A.V.; Kovaleva, O.V.; Laktionov, K.K.; Mochalnikova, V.V.; Komelkov, A.V.; Tchevkina, E.M. Zborovskaya and I.B. “Arf6, RalA, and BIRC5 protein expression in nonsmall cell lung cancer. Mol. Biol., 2011, 45(2), 275-282.
[http://dx.doi.org/10.1134/S0026893310061032]
[29]
Zhu, Y.; Li, Y.; Zhu, S.; Tang, R.; Liu, Y.; Li, J. Association of survivin polymorphisms with tumor susceptibility: a meta-analysis. PLoS One, 2013, 8(9), e74778.
[http://dx.doi.org/10.1371/journal.pone.0074778] [PMID: 24098667]
[30]
Dai, J.; Jin, G.; Dong, J.; Chen, Y.; Xu, L.; Hu, Z.; Shen, H. Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival. J. Thorac. Oncol., 2010, 5(11), 1748-1754.
[http://dx.doi.org/10.1097/JTO.0b013e3181f18cb9] [PMID: 20881643]
[31]
Yang, X.; Xiong, G.; Chen, X.; Xu, X.; Wang, K.; Fu, Y.; Yang, K.; Bai, Y. Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J. Cancer Res. Clin. Oncol., 2009, 135(10), 1341-1349.
[http://dx.doi.org/10.1007/s00432-009-0575-7] [PMID: 19352701]
[32]
Jang, J.S.; Kim, K.M.; Kang, K.H.; Choi, J.E.; Lee, W.K.; Kim, C.H.; Kang, Y.M.; Kam, S.; Kim, I.S.; Jun, J.E.; Jung, T.H.; Park, J.Y. Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer, 2008, 60(1), 31-39.
[http://dx.doi.org/10.1016/j.lungcan.2007.09.008] [PMID: 17961802]
[33]
Li, Y.; Wang, J.; Jiang, F.; Lin, W.; Meng, W. Association of polymorphisms in survivin gene with the risk of hepatocellular carcinoma in Chinese han population: a case control study. BMC Med. Genet., 2012, 13(1), 1.
[http://dx.doi.org/10.1186/1471-2350-13-1] [PMID: 22214342]
[34]
Abdelfattah, A.A.M.; Rizk, F.; Hawash, N.; Hanafy, A.; El-Kalla, F.; Abd-Elsalam, S. Randomized trial of preoperative administra-tion of oral pregabalin for postoperative analgesia in patients sche-duled for radiofrequency ablation of focal lesions in the liver. Int. J. Hyperthermia, 2018, 34(8), 1367-1371.
[35]
Negm, O.; Abou Saif, S.; El Gharib, M.; Yousef, M.; Abd-Elsalam, S. Role of low-molecular-weight heparins in prevention of throm-boembolic complication after transarterial chemoembolization in hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol., 2017, 29(3), 317-321.

Rights & Permissions Print Cite
Article Metrics
18
2
1
© 2024 Bentham Science Publishers | Privacy Policy